Several studies have proposed and shown the efficacy of inhibiting CHEK1 in TP53 wildtype and deleted in vitro and in vivo CLL cells, which could be considered as an additional combination treatment option [15,16,17]. This evidence concerns the gene CHEK1 and B-cell chronic lymphocytic leukemia.